medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 4

<< Back Next >>

Ann Hepatol 2012; 11 (4)

Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative

Bessone F, Hernandez N, Dávalos M, Paraná R, Schinoni MI, Lizarzabal M, Kershenobich D, Loaeza A, Arrese M, Chirino RA, Méndez-Sánchez N, Fay F, Bruguera M, Stephens C, Lucena MI, Andrade RJ

Language: English
References: 24
Page: 544-549
PDF size: 88.22 Kb.


Text Extraction

INTRODUCTION
Latin America lacks a centralized database registry capable of reliably accounting for the incidence and particular characteristics of drug-induced liver damage within the region. Collaborative efforts, consensus- based diagnostic criteria and a standardized nomenclature are the essential components to perform this task.


REFERENCES

  1. Galan MV, Potts JA, Silverman, Gordon GC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005; 39: 64-7.

  2. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, et al. Drug-induced liver injury: an analysis of 46 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005; 129: 512-21.

  3. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731-5.

  4. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-43.

  5. Suzuki A, Andrade RJ, Björnsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBaseTM: unified list based on international collaborative work. Drug Saf 2010; 33: 503-22.

  6. Bessone F, Colombato L, Fassio E, Reggiardo MV, Vorobioff J, Tanno H. The spectrum of nimesulide-induced-hepatotoxicity. An overview. Anti-Inflamm & Anti-Allergy Agents Med Chem 2010; 9: 355-65.

  7. Bessone F, Tanno H. Hepatotoxicidad inducida por antiinflamatorios no esteroides. Gastroenterol Hepatol 2000; 23: 200-5.

  8. Bessone F. Non-Steroideal Anti-inflammatory Drugs (NSAIDs): What is the actual risk of liver damage? World J Gastroenterol 2010; 16(45): 5651-61.

  9. Walker SL, Kennedy F, Niamh N, McCormick A. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol and Drug Saf 2008; 17: 1108-12.

  10. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury (DILI). Clin Pharmacol Ther 2011; 55: 683-91.

  11. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319: 1541.

  12. Banks AT, Zmmerman HJ, Ihak KG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-7.

  13. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How Common Is Diclofenac-Associated Liver Injury? Analysis of 17.289 Arthritis Patients in a Long- Term Prospective Clinical Trial. Am J Gastroenterol 2009; 104: 356-62.

  14. Lucena MI, Cohen H, Hernández N, Bessone F, Dacoll C, Stephens C, Borraz Y, et al. Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterol Hepatol 2011; 34(5): 361-8.

  15. Drug Induced Liver Injury Network (DILIN). Available from: http://dilin.dcri.duke.edu/web

  16. Asociación Latinoamericana de Hepatología (ALEH). Available from: http://www.kenes.com/alehigado_/ historia.htm

  17. International Serious Adverse Events Consortium (iSAEC). Available from: http://www.saeconsortium.org/

  18. Burroughs V, Maxey R, Levy R. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002; 94(10 Suppl.): 1-26.

  19. Daly A, Day C. Genetic Association Studies in Drug-Induced Liver Injury. Semin Liver Dis 2009; 29: 400-11.

  20. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53: 1049-53.

  21. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, Daly MJ, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9.

  22. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, et al. Susceptibility to amoxicillin-clavulanate- induced liver injury is influenced by multiple hla class I and II alleles. Gastroenterology 2011; 141: 338-47.

  23. Stephens C, Lopez-Nevot MI, Lucena MI, Ruiz-Cabello F, Ulzurrun E, Cabello MC, Lucena MI, et al. The HLA class I B*1801 allele influences hepatocellular expression of amoxicillin- clavulanate liver damage and outcome in Spanish patients. J Hepatol 2010; 52: S439.

  24. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced Liver Injury: Insights from genetic studies. Pharmacogenomics 2009; 10: 1467-87.




2020     |     www.medigraphic.com